COMPASS THERAPEUTICS, INC. Restricted Cash and Cash Equivalents
COMPASS THERAPEUTICS, INC. (CMPX) had Restricted Cash and Cash Equivalents of $568.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-06
- 2026-06-30: Restricted Cash and Cash Equivalents $568.00K.
- 2026-03-31: Restricted Cash and Cash Equivalents $568.00K.
- 2025-12-31: Restricted Cash and Cash Equivalents $568.00K.
- 2025-09-30: Restricted Cash and Cash Equivalents $568.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $568.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $568.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $568.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $568.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $568.00K 10-Q · filed 2026-08-06 |
| 2025-03-31 | $568.00K 10-Q · filed 2026-05-05 |
| 2024-12-31 | $568.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 |
| 2024-03-31 | $320.00K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |